> Pieris Pharmaceuticals ($PIRS) wrapped up its uplisting from OTCQB to Nasdaq, adding $25 million (€23 million) before costs to its bank account in the process. Freising, Germany-based Pieris plans to use the cash to fund the advance of its pipeline assets, all of which are based upon its Anticalin technology. In a separate development, Daiichi Sankyo handed over the seventh milestone payment in its collaboration with Pieris after an asset generated positive preclinical proof-of-concept data. Release | More
> NeuroDerm ($NDRM) filed for a secondary offering that would add up to $50 million (€45 million) to its bank balance. The Israeli biotech joined Nasdaq with a whimper in November--raising $45 million in an IPO that priced well below its target range--but ended the year by posting Phase IIa data that drove a jump in its share price. With the stock now trading around the price NeuroDerm was aiming for when it went public, it has decided to re-up to finance the advance of its Parkinson's disease assets towards regulatory filings. F-1 | Globes
> Oasmia Pharmaceutical joined the ever-growing list of European biotechs to turn up on Wall Street. Uppsala, Sweden-based Oasmia is seeking up to $23 million (€21 million) to fund clinical trials of its pipeline of oncology assets for humans and animals. The human health programs are set to scoop up the largest slices of the IPO haul, with Oasmia setting aside $3 million for development of a pairing of docetaxel and its drug delivery system, XR-17. F-1
> Chiasma tweaked its IPO expectations. The Israeli-American biotech will now pocket $92 million (€83 million) if the overallotment is taken up in full, $6 million more than it was aiming for when it first filed last month. Chiasma also added a breakdown of how it plans to allocate the cash to its filing, revealing that it will commit around one-third of the maximum possible haul to building out its corporate infrastructure ahead of the anticipated approval of its acromegaly treatment. A further $15 million is earmarked for a trial to support a regulatory filing in Europe. S-1/A | Globes
> 4SC pulled in €29 million ($32 million) to finance a Phase II trial of its lead oncology asset, resminostat, in patients with cutaneous T-cell lymphoma (CTCL). New investor Wellington Partners hoovered up €5 million worth of the shares, helping 4SC to hit the upper end of its fundraising aspirations. 4SC has made development in CTCL the short-term objective for resminostat, an oral histone-deacetylase inhibitor. In the longer term, 4SC is going after the much bigger indication of liver cancer. Release (PDF)
> Abingworth named Tim Haines and Kurt von Emster as its joint managing partners. The pair replace Stephen Bunting, who is stepping into the role of chairman after holding the managing partner post for 13 years. Haines has worked as a partner out of Abingworth's London office for a decade, before which he was CEO of one of its portfolio companies, Astex Therapeutics. Von Emster is a more recent appointment, having started at Abingworth's California office in January. Release
> Gensight Biologics filed for an IPO on Nasdaq to finance development of a pair of gene therapies against orphan diseases of the eye. Paris, France-based Gensight is on the cusp of advancing its lead candidate into Phase III, just months after it wrapped up a Phase Ib study to assess the therapy. The program is aiming to treat Leber hereditary optical neuropathy (LHON) by delivering a copy of the ND4 gene. Santhera Pharmaceuticals (SIX:SANN) is also going after LHON and is closing in on an approval in Europe. FierceBiotech